Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Heron Therapeutics (HRTX) over the last 11 years, with Q3 2025 value amounting to $1.1 million.

  • Heron Therapeutics' Change in Receivables rose 11673.41% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year increase of 33181.26%. This contributed to the annual value of $18.7 million for FY2024, which is 13175.07% up from last year.
  • Heron Therapeutics' Change in Receivables amounted to $1.1 million in Q3 2025, which was up 11673.41% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Change in Receivables ranged from a high of $25.2 million in Q2 2023 and a low of -$12.9 million during Q3 2023
  • In the last 5 years, Heron Therapeutics' Change in Receivables had a median value of $1.1 million in 2025 and averaged $2.1 million.
  • Examining YoY changes over the last 5 years, Heron Therapeutics' Change in Receivables showed a top increase of 325562.5% in 2023 and a maximum decrease of 78424.4% in 2023.
  • Over the past 5 years, Heron Therapeutics' Change in Receivables (Quarter) stood at -$7.6 million in 2021, then soared by 229.97% to $9.9 million in 2022, then crashed by 137.1% to -$3.7 million in 2023, then soared by 423.73% to $11.8 million in 2024, then tumbled by 90.58% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.2 million for Q2 2025, and -$145000.0 during Q1 2025.